Gour Medical SA and the French National Center for Scientific Research (CNRS) via the Baculovirus and Therapy Lab start a research partnership

to develop and manufacture a recombinant monoclonal antibody for therapeutic use: anti-IgE chimeric antibody for dogs with potential use in the veterinary field

May 7th , 2015: ZUG, Switzerland – Gour Medical SA, a veterinary biomedical company, announced today the signing of a first research partnership with CNRS for the development of recombinant monoclonal antibody for therapeutic use on dogs and cats.

Gour plans to develop a therapeutic recombinant chimeric monoclonal antibody and to launch it in the market. A first product is under development for the treatment of Atopic Dermatitis for dogs, a substantial and still unmet medical need.

As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the recombinant chimeric antibody in this indication.

About Gour Medical SA

Gour Medical SA, founded in 2014, is a Swiss based veterinary biomedical company leveraging the advances in human research and applying them to medical solutions for companion animals. Integrated and innovative therapeutic solutions developed by Gour address companion animals' unmet medical needs by treating or preventing their most significant health issues.

Download Press Release document : Gour Medical_CNRS – PR-English 20150507

Version Française: Gour Medical_CNRS – Francais 07052015

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…